TABLE 2.

Cytotoxicity and anti-HBV effect of NVR 3-778 in HBV-infected PHHs in the presence and absence of plasma proteins^a

Condition	Cytotoxicity (CC50 [μM])b				EC50 for extracellular HBV DNA (μM)c				EC90 for extracellular HBV DNA (μM)c
	Days 0–8		Days 5–12		Days 0–8		Days 5–12		Days 0–8		Days 5–12
	Mean (95% CI)	Fold change	Mean (95% CI)	Fold change	Mean (95% CI)	Fold change	Mean (95% CI)	Fold change	Mean (95% CI)	Fold change	Mean (95% CI)	Fold change
no BSA, no hA1GP	15.85 (14.32–17.55)		>25		1.256 (0.792–1.945)		0.906 (0.562–1.338)		4.660 (2.356–15.740)		4.267 (2.142–13.940)
4.3% BSA + 0.07% hA1GP	53.72 (48.92–58.99)	3.4	81.68 (67.98–98.15)	>3	4.379 (3.567–5.406)	3.5	2.468 (2.042–2.903)	2.7	12.133 (8.236–20.324)	2.6	9.451 (7.111–13.274)	2.2
8% BSA + 0.07% hA1GP	81.54 (74.25–89.54)	5.1	101.30 (89.88–114.10)	>3	5.868 (4.831–7.066)	4.7	3.712 (2.598–4.876)	4.1	19.364 (13.335–32.137)	4.2	20.137 (12.445–41.880)	4.7

^aData represent mean values of three or more independent experiments, and 95% confidence intervals (CI) are in parentheses.

^bCytotoxicity was assessed by measurement of the ATP content. Fold change represents the change in the mean 50% cytotoxic concentration (CC₅₀) in the presence of plasma proteins compared to the value in the absence of plasma proteins.

^cExtracellular HBV DNA was analyzed by extraction of DNA from the cell culture supernatant and quantified by qPCR. Fold change represents the value in the presence of plasma proteins compared to that in the absence of plasma proteins. EC₅₀, 50% effective concentration; EC₉₀, 90% effective concentration.